What P1 Trials does

P1 Trials (rebranded as P1 Pratia Oncology in December 2025) is a Seattle-headquartered, Delaware-incorporated clinical research site network that enables community-based oncology clinics to conduct complex Phase 1 oncology trials. The company operates as a managed-services intermediary, providing eight integrated service modules — feasibility assessments, regulatory support, contracts and budgets, financial management, business development, technology integration, quality management, and patient matching/screening — to community oncology practices that lack the infrastructure to run early-phase studies independently. P1 Trials' stated mission is to bring investigational therapies closer to patients outside academic medical centers by bridging sponsor demand with community-site supply.

The platform is built on a centralized infrastructure layer that includes a Clinical Trial Management System (CTMS) and an AI-based patient matching recommendation engine that processes structured patient data to identify relevant trial opportunities across the network. Service delivery is handled through direct enterprise sales to pharmaceutical sponsors and CROs, with industry conferences used as a secondary channel for business development. The customer base is dual-sided: pharmaceutical sponsors seeking faster enrollment and access to community-based patient populations, and community oncology clinics seeking the operational scaffolding, regulatory expertise, and sponsor relationships needed to participate in Phase 1 research.

Revenue is generated through quote-based B2B managed-services arrangements with pharmaceutical sponsors and CROs, monetized via per-trial service fees and centralized operational support for affiliated community clinics. In December 2025, P1 Trials joined Pratia, a global early-phase oncology research site network, and rebranded as P1 Pratia Oncology; Pratia now functions as the parent operating company, granting P1 multi-geography sponsor access and shared operational infrastructure. The company has raised $5,454,015 in an SEC Rule 506(b) exempt equity offering with a single investor, with first sale recorded on November 26, 2025.

Name

P1 Trials

Legal name

P1 Trials, Inc.

Website

https://p1trials.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

P1 Trials (now P1 Pratia Oncology) is a Seattle-based clinical research site network that enables community oncology clinics to run Phase 1 oncology trials, providing centralized regulatory, financial, technology, and AI patient-matching services to both clinics and pharmaceutical sponsors.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Offices of Physicians (62111), Scientific Research and Development Services (5417)

SIC

Services-Health Services (8000), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts) (HLAGACAC), Clinical Trial Financial Management & Payments (Site Budgeting) (HLAGACAM), Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI)

Keywords

• Phase 1 oncology trials
• Clinical trial site network
• Community oncology research
• Patient trial matching
• Clinical research services

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Clinical Trial Support Services: P1 Trials generates revenue by providing centralized services to community oncology clinics conducting Phase 1 clinical trials. Services include feasibility assessments, regulatory support, contracts and budgets, financial management, business development, technology integration, quality management, and patient matching. The company acts as an intermediary between pharmaceutical sponsors seeking trial sites and community clinics seeking trial opportunities.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

P1 Trials operates a centralized, community-based oncology clinic network purpose-built to run Phase 1 clinical trials. It delivers feasibility, regulatory, contracts and budget, financial management, business development, technology integration, quality management, and clinic enablement services, augmented by AI-powered patient matching, giving sponsors access to community oncology patient populations that traditional academic centers typically do not reach.

Product overview

P1 Trials (now P1 Pratia Oncology) operates as a unified platform for Phase 1 oncology clinical trials, combining a network of community-based oncology clinics with centralized infrastructure services. The platform comprises eight integrated service modules: Feasibility Assessments, Regulatory Support, Contracts & Budgets, Financial Management, Business Development, Technology Integration, Quality Management, and Patient Matching & Screening. Together, these services enable community clinics to participate in Phase 1 clinical trials by handling operational complexities, regulatory compliance, financial processes, and patient recruitment—allowing clinics to focus on patient care while the centralized infrastructure manages trial execution.

Differentiator

Problem solved

Functional benefit

Products and services

• Phase 1 Oncology Clinical Trial Site Network Services

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

Partnerships

One partnership is on record.

• PratiacoreStrategic or Co-development Partner · 1 December 2025In December 2025, P1 Trials joined Pratia, expanding reach and capabilities as part of a global early-phase oncology Research Site Network. The partnership enables P1 Trials (now P1 Pratia Oncology) to leverage Pratia's global network infrastructure while maintaining its focus on community-based oncology clinics in the US.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Sarah Cannon Research Institute (SCRI): One of the largest Phase 1 oncology site networks in the US, operating dedicated early-phase units across multiple cities. Directly comparable as a multi-site Phase 1 oncology research organization targeting pharmaceutical sponsors.
• NEXT Oncology: Network of dedicated Phase 1 oncology centers conducting first-in-human and early-phase trials. Highly comparable business model focused on early-phase oncology trial execution and sponsor access.
• START (South Texas Accelerated Research Therapeutics): Global early-phase oncology research organization running Phase 1 trials across multiple sites. Directly comparable as a Phase 1-focused oncology site network serving pharma sponsors.
• Florida Precision Oncology: Phase 1 oncology research site network with multiple community-based locations across Florida. Comparable as a multi-site Phase 1 oncology site operator targeting pharma sponsors.

Emerging players

• Exigent Research: Innovative research network of independent oncology practices; an advisor to P1 (Sibel Blau, MD) is a founding member. Comparable model aggregating independent community oncology clinics for clinical research.
• ONCare Alliance: National organization focused on community oncology research, value-based care, and education; P1 leadership has prior involvement. Comparable as a community oncology research network and ecosystem peer.

Broad incumbents

• IQVIA (Oncology / Site Solutions): Global CRO with dedicated site management and oncology clinical trial services. Comparable as a broad incumbent offering site-network services to pharma sponsors, though not Phase 1 oncology focused.
• MD Anderson Cancer Center: Premier academic Phase 1 oncology site; relevant incumbent that anchors sponsor preference for early-phase oncology trials. Indirect competitive pressure on community-based Phase 1 models like P1.

Regional players

• Northwest Medical Specialties: Multi-clinic community oncology practice in Washington state with a Phase 1 research program; P1's CMO previously served there. Highly relevant comparable as a community oncology clinic running Phase 1 trials.

Others

• Pratia: Global early-phase oncology research site network that P1 joined in December 2025 as P1 Pratia Oncology. Functions as both partner and parent strategic operating company, shaping P1's distribution and capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about P1 Trials